Esteban Martinez

Summary

Affiliation: Infectious Diseases Unit
Country: Spain

Publications

  1. ncbi Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
    Esteban Martinez
    Hospital Clinic, Barcelona, Spain
    AIDS 21:367-9. 2007
  2. ncbi Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir
    Esteban Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, 08036 Barcelona, Spain
    AIDS Res Hum Retroviruses 29:235-41. 2013
  3. ncbi Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
    Esteban Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, Spain
    AIDS 26:2315-26. 2012
  4. ncbi Effectiveness of lipid-lowering therapy in HIV patients
    Esteban Martinez
    Infectious Diseases Unit, IDIBAPS Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
    Curr Opin HIV AIDS 3:240-6. 2008
  5. ncbi Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients
    Paula Freitas
    Endocrinology, Diabetes and Metabolism Department of Centro Hospitalar São João, E P E, University of Porto Medical School, Alameda Hernani Monteiro, 4200 319 Porto, Portugal
    BMC Infect Dis 11:246. 2011
  6. ncbi The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    AIDS 24:353-63. 2010
  7. ncbi Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    AIDS 24:F1-9. 2010
  8. ncbi Cardiovascular disease and HIV infection: host, virus, or drugs?
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Curr Opin Infect Dis 22:28-34. 2009
  9. ncbi A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression
    Esteban Martinez
    Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, Spain
    J Acquir Immune Defic Syndr 51:290-7. 2009
  10. ncbi Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir
    Esteban Martinez
    Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, Valencia, Spain
    Clin Infect Dis 38:1017-23. 2004

Detail Information

Publications85

  1. ncbi Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
    Esteban Martinez
    Hospital Clinic, Barcelona, Spain
    AIDS 21:367-9. 2007
    ..In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation...
  2. ncbi Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir
    Esteban Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, 08036 Barcelona, Spain
    AIDS Res Hum Retroviruses 29:235-41. 2013
    ..2744). The results of this analysis do not suggest that outcomes of abacavir/lamivudine are worse than those of tenofovir/emtricitabine when combined with raltegravir in virologically suppressed HIV-infected adults...
  3. ncbi Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
    Esteban Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, Spain
    AIDS 26:2315-26. 2012
    ..Switching from boosted protease inhibitors (PI/r) to raltegravir (RAL) results in a better plasma lipid profile than continuing PI/r. Whether this strategy affects plasma biomarkers associated with atherosclerosis is unknown...
  4. ncbi Effectiveness of lipid-lowering therapy in HIV patients
    Esteban Martinez
    Infectious Diseases Unit, IDIBAPS Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
    Curr Opin HIV AIDS 3:240-6. 2008
    ..The aim of this article is to analyse the effectiveness of lipid-lowering therapy in HIV-infected patients...
  5. ncbi Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients
    Paula Freitas
    Endocrinology, Diabetes and Metabolism Department of Centro Hospitalar São João, E P E, University of Porto Medical School, Alameda Hernani Monteiro, 4200 319 Porto, Portugal
    BMC Infect Dis 11:246. 2011
    ..This study aimed to evaluate the prevalence of the metabolic syndrome (MS) and its components, and to determine whether patients with or without CL had a different prevalence of MA...
  6. ncbi The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    AIDS 24:353-63. 2010
    ..To assess the effects of decreased antiretroviral therapy exposure on body fat and metabolic parameters...
  7. ncbi Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    AIDS 24:F1-9. 2010
    ..To assess the effects of initiating abacavir-containing therapy on plasma lipids and cardiovascular biomarkers...
  8. ncbi Cardiovascular disease and HIV infection: host, virus, or drugs?
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Curr Opin Infect Dis 22:28-34. 2009
    ..We review the risk of cardiovascular disease in HIV-infected persons compared with that in uninfected persons and discuss the relative contributions of host, HIV, and antiretroviral therapy in the light of current knowledge...
  9. ncbi A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression
    Esteban Martinez
    Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, Spain
    J Acquir Immune Defic Syndr 51:290-7. 2009
    ..We compared 48-week efficacy and safety of these combinations as substitutes of nucleosides in patients with virological suppression...
  10. ncbi Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir
    Esteban Martinez
    Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, Valencia, Spain
    Clin Infect Dis 38:1017-23. 2004
    ..These findings may have clinical implications when the therapeutic option of lopinavir-ritonavir is considered...
  11. ncbi Objective amount of limb fat in HIV-infected subjects with subjective diagnosis of lipoatrophy
    E Martinez
    Infectious Diseases Unit, Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    HIV Med 10:257-61. 2009
    ..The relationship between the subjective diagnosis of lipoatrophy and the objective amount of limb fat loss in HIV-infected adults is unclear...
  12. ncbi Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area
    E Martinez
    Infectious Diseases Unit, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic Universitari, Barcelona, Spain
    HIV Med 8:251-8. 2007
    ....
  13. ncbi [Lipid profile of atazanavir]
    Esteban Martínez Chamorro
    Servicio de Infecciones, Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, Universidad de Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:34-40. 2008
    ....
  14. ncbi Retroviruses and opportunistic infections - 13th annual meeting
    Esteban Martinez
    University of Barcelona, Infectious Diseases Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    IDrugs 9:250-2. 2006
  15. ncbi The reassurance of experience
    E Martinez
    Infectious Diseases Unit, Hospital Clinic IDIBAPS, Barcelona, Spain
    Int J STD AIDS 14:20-8. 2003
    ..Stavudine has a low incidence of clinically significant adverse events, and those experienced are generally long-term, manageable class effects...
  16. ncbi Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors
    Esteban Martinez
    Hospital Clinic IDIBAPS, Barcelona, Spain
    Antivir Ther 8:403-10. 2003
    ..Whether a therapeutic approach addressed to those metabolic abnormalities may have any impact on body fat is not clear...
  17. ncbi Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    N Engl J Med 349:1036-46. 2003
    ..We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in whom virologic suppression had been achieved...
  18. ncbi Disorders of fat partitioning in treated HIV-infection
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Best Pract Res Clin Endocrinol Metab 25:415-27. 2011
    ..Surgical filling cosmetically improves facial lipoatrophy. Exercise and diet may reduce increased visceral adipose tissue. Liposuction may be useful to remove superficial, localized fat accumuli...
  19. ncbi Influenza A H1N1 in HIV-infected adults
    E Martinez
    Infectious Diseases Unit, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    HIV Med 12:236-45. 2011
    ..We aimed to compare epidemiological data, clinical characteristics, and outcomes of influenza A H1N1 infection between HIV-infected and -uninfected adults...
  20. ncbi Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clínic Institut d Investigaciones Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 24:1697-707. 2010
    ..Switching to raltegravir in selected patients treated with ritonavir-boosted protease inhibitors may result in similar efficacy and lower plasma lipids...
  21. ncbi Simplification of antiretroviral therapy with etravirine
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, University of Barcelona IDIBAPS, Barcelona, Spain
    AIDS Rev 12:52-9. 2010
    ..Long-term trials are necessary to confirm the role of etravirine in simplification strategies, but preliminary clinical data is reassuring...
  22. ncbi The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients
    Ana Milinkovic
    Infectious Diseases Unit, Hospital Clinic Barcelona, Barcelona, Spain
    Antivir Ther 12:407-15. 2007
    ..We assessed the safety and efficacy of reducing the dose of stavudine compared with switching to tenofovir or maintaining the standard dose of d4T...
  23. ncbi Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine
    Agathe Leon
    Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Spain
    AIDS 19:213-5. 2005
    ..These results argue against the use of tenofovir plus didanosine in HIV-infected antiretroviral-naive adults even when the third drug is a non-nucleoside reverse transcriptase inhibitor...
  24. ncbi Mitochondrial effects of antiretroviral therapies in asymptomatic patients
    Sonia Lopez
    Muscle Research Unit, Department of Internal Medicine, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute IDIBAPS, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain
    Antivir Ther 9:47-55. 2004
    ..A decrease in the mitochondrial (mt) DNA to nuclear DNA ratio has gained acceptance as a marker of mitochondrial toxicity in treated HIV-infected patients, but the functional meaning of this alteration is unclear...
  25. ncbi Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin
    Montserrat Laguno
    Infectious Diseases Service, Hospital Clinic Universitari de Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:174-8. 2007
    ..Few data are available in HIV/HCV-coinfected patients, however...
  26. ncbi Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients
    Montserrat Laguno
    Infectious Diseases Unit, Hospital Clinic, Villarroel, 170, Barcelona, Spain
    AIDS Res Hum Retroviruses 24:547-53. 2008
    ..Despite the high prevalence, this phenomenon does not seem to affect the clinical evolution of chronic hepatitis C or modify the viral response to interferon-based HCV therapies..
  27. ncbi Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
    Josep Mallolas
    Hospital Clinic Universitari IDIBAPS, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 51:29-36. 2009
    ..To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r...
  28. ncbi High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir
    Agathe Leon
    Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Spain
    AIDS 19:1695-7. 2005
    ..These results argue against the use of tenofovir-didanosine not only in naive patients, but also in previously suppressed patients...
  29. ncbi Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations
    Jose Luis Blanco
    Infectious Diseases Unit, University of Barcelona, Spain
    AIDS 20:1891-2. 2006
    ..0152) or thymidine-associated (P = 0.0142) mutations. In conclusion, ddI retained substantial antiretroviral activity when the number of nucleoside-associated or thymidine-associated mutations was less than four...
  30. ncbi Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir
    Maria Saumoy
    Infectious Disease Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
    Antivir Ther 16:459-68. 2011
    ....
  31. ncbi Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients
    Maria Larrousse
    Infectious Diseases Unit, Hospital Clínic Universitari de Barcelona IDIBAPS, University of Barcelona, Spain
    J Acquir Immune Defic Syndr 46:304-11. 2007
    ..Several serum markers reflecting extracellular matrix status have been correlated with liver fibrosis in non-HIV-infected patients with chronic hepatitis C infection. These indexes have been less examined in HIV/HCV-coinfected individuals...
  32. ncbi In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis
    Oscar Miro
    Mitochondrial Research Laboratory, Hospital Clinic, IDIBAPS, Barcelona, Catalonia, Spain
    Antivir Ther 10:945-51. 2005
    ....
  33. ncbi Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Calle Villarroel 170, 08036 Barcelona, Spain
    Lancet 364:65-7. 2004
    ..666, 95% CI 1.246-91.294, p=0.031). These results suggest that the risk of pancreatitis is heightened when didanosine and tenofovir are given together...
  34. ncbi Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine
    Oscar Miro
    Mitochondrial Research Laboratory, Muscle Research Unit, Department of Internal Medicine, Hospital Clinic, Institut d Investigations Bioiuèdiques August Pi I Sunyer, Barcelona, Spain
    J Acquir Immune Defic Syndr 37:1550-5. 2004
    ..These data suggest that upregulatory transcriptional or posttranscriptional mechanisms compensate for mtDNA depletion caused by d4T + ddI before profound mtDNA depletion occurs...
  35. ncbi Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor
    Jose L Blanco
    Infectious Diseases Service, IDIBAPS, Hospital Clinic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
    AIDS 19:829-31. 2005
    ..Only one of the 66 patients developed changes in their pattern of mutations able to generate or increase resistance to new drugs...
  36. ncbi Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption
    Agathe Leon
    Infectious Diseases Department, Hospital Clinic of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Antimicrob Chemother 63:184-8. 2009
    ..CD4+ T cell recovery dynamics were analysed during the 'on treatment' periods in structured therapy interruption (STI) as well as the long-term immune reconstitution with highly active antiretroviral therapy (HAART) after finishing STI...
  37. ncbi Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count
    Felipe Garcia
    Clinic Institute of Infectious Diseases and Immunology, IDIBAPS, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    J Acquir Immune Defic Syndr 36:702-13. 2004
    ..It seems that the immune recovery slows down after approximately 3 years of HAART and reaches a plateau after 4-5 years of HAART...
  38. ncbi Association between physical and echographic fat thickness assessments and a lipodystrophy grading scale in lipodystrophic HIV patients: practical implications
    Victor Asensi
    Infectious Diseases Unit, Hospital Central de Asturias, Oviedo University School of Medicine, Barcelona, Spain
    AIDS Res Hum Retroviruses 22:830-6. 2006
    ..The combination of these subjective and objective parameters could be helpful in the early detection of lipodystrophy in clinical practice...
  39. ncbi Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients
    Montserrat Laguno
    Infectious Diseases, University of Barcelona, Spain
    AIDS Res Hum Retroviruses 28:1294-300. 2012
    ..There is a risk of sexual transmission of HCV in HIV-infected men who have sex with men. In our experience, early treatment of AHC with pegylated interferon-alfa plus ribavirin in HIV patients achieves poor results...
  40. ncbi [Current status of acute hepatitis C]
    María Martínez-Rebollar
    Servicio de Infecciones, Hospital Clinic, Barcelona, Espana
    Enferm Infecc Microbiol Clin 29:210-5. 2011
    ..The optimal treatment regimen (interferon alone or combined with ribavirin) and its duration are not clearly established at the present time...
  41. ncbi Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial
    Adrian Curran
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 17:711-8. 2012
    ....
  42. ncbi Short Communication: Natural killer cells and expression of KIR receptors in chronic HIV type 1-infected patients after different strategies of structured therapy interruption
    Gabriel Mestre
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 24:1485-95. 2008
    ..This finding suggests that STI could decrease the number of NK subsets, which is related to the worst clinical development in these patients...
  43. ncbi Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia
    Gloria Garrabou
    Mitochondrial Research Laboratory, Internal Medicine Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona and CIBER de Enfermedades Raras, CIBERER, Barcelona, Spain
    J Acquir Immune Defic Syndr 52:443-51. 2009
    ....
  44. ncbi Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis
    Marylène Lejeune
    Immunology Service, Hospital Clinic Institut d Investigacions Biomèdiques Augustí Pi i Suñer, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 52:662-70. 2011
    ..It is unknown whether a Toxoplasma gondii-specific T cell response is restored after successful combined antiretroviral therapy (cART) in patients with AIDS and current or previous toxoplasmic encephalitis (TE)...
  45. ncbi Mitochondrial assessment in asymptomatic HIV-infected paediatric patients on HAART
    Constanza Moren
    Mitochondrial Functionalism Laboratory, Universitat de Barcelona, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Antivir Ther 16:719-24. 2011
    ..We aimed to determine whether mtDNA and mitochondrial function abnormalities are present in peripheral blood mononuclear cells from asymptomatic HIV-infected children...
  46. ncbi Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults
    Elena Ferrer
    HIV Unit, Service of Infectious Diseases, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:1061-5. 2011
    ..008) and subcutaneous fat (42%, p = 0.008). These data suggest that switching from LPV/r to ATV/r is associated with increased trunk fat, both subcutaneous and visceral...
  47. ncbi Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals
    Oscar Miro
    Mitochondrial Research Laboratory, Muscle Research Unit, Department of Internal Medicine, Hospital Clinic, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    Clin Infect Dis 39:710-6. 2004
    ..001), along with increased lipid peroxidation of PBMC membranes (P=.007). Therefore, HIV infection is associated not only with mtDNA depletion, but also with extensive MRC disturbances and increased oxidative damage...
  48. ncbi Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1
    Jordi Blanch
    Clinical Institute of Psychiatry and Psychology, Hospital Clinic Universitari de Barcelona, 08036 Barcelona, Spain
    Clin Infect Dis 38:1464-70. 2004
    ..Specific characteristics of patients, antiretroviral-based side effects, and breast lipoaccumulation exert a greater impact on QoL in HIV-1-infected patients with LD...
  49. ncbi Short communication: HIV infection, antiretrovirals, and apoptosis: studies on skeletal muscle
    Oscar Miro
    Mitochondrial Research Laboratory, Muscle Research Unit, Department of Internal Medicine, Hospital Clinic, IDIBAPS, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 21:702-5. 2005
    ..We conclude that skeletal muscle of HIV-infected patients exhibits increased apoptosis compared with that of uninfected patients, but the role of HAART in inducing apoptosis remains to be established...
  50. ncbi Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients
    Montse Laguno
    Infectious Diseases Unit, Hospital Clinic Barcelona, Barcelona, Spain
    Antivir Ther 10:423-9. 2005
    ....
  51. ncbi Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women
    María Martínez-Rebollar
    Infectious Diseases Service, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Ther Drug Monit 33:772-7. 2011
    ..No vertical transmissions were reported. Therapeutic drug monitoring of SQV during pregnancy should be considered, mainly during the third trimester, to ensure adequate drug exposure throughout the entire pregnancy...
  52. ncbi Mitochondrial damage in adipose tissue of untreated HIV-infected patients
    Gloria Garrabou
    Mitochondrial Research Laboratory, Internal Medicine Department, Muscle Research Unit, IDIBAPS, University of Barcelona, Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Raras, Spain
    AIDS 25:165-70. 2011
    ..However, the viral capacity to induce adipose tissue mitochondrial lesion is still a matter of doubt. We aimed to assess whether untreated HIV infection was associated with adipose tissue mitochondrial abnormalities...
  53. ncbi Use of diet, nutritional supplements and exercise in HIV-infected patients receiving combination antiretroviral therapies: a systematic review
    Pere Leyes
    Nutrition and Dietetics Unit, Endocrinology Service, Hospital Clinic de Barcelona, 08036 Barcelona, Spain
    Antivir Ther 13:149-59. 2008
    ..Nutritional status could influence body composition changes...
  54. ncbi Improvement of psychosocial adjustment to HIV-1 infection through a cognitive-behavioral oriented group psychotherapy program: a pilot study
    Araceli Rousaud
    Fundació Clínic per la Recerca Biomèdica IDIBAPS, Institut d Investigacions Biomèdiques Agustí Pi i Sunyer, Hospital Clinic de Barcelona, Barcelona, Spain
    AIDS Patient Care STDS 21:212-22. 2007
    ..Our psychotherapy program improved psychosocial functioning in a heterogeneous sample of HIV-1-infected patients referred to a consultation-liaison psychiatry unit...
  55. ncbi Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy
    Esteban Martinez
    Infectious Diseases, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Antivir Ther 9:649-63. 2004
    ..Development of new PIs with more favourable effects on the lipid profile should be of benefit...
  56. ncbi Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy
    Adrian Curran
    Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Infectious Diseases Department, Spain
    AIDS 26:475-81. 2012
    ..To compare 48-week changes in body fat distribution and bone mineral density (BMD) between patients switching from a ritonavir-boosted protease inhibitor (PI/r) to raltegravir (RAL) and patients continuing with PI/r...
  57. ncbi Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C
    Montserrat Laguno
    Infectious Diseases Unit, Hospital Clinic Universitari de Barcelona, Barcelona, Spain
    Antivir Ther 9:905-9. 2004
    ..In this study, we evaluated the incidence and management of depressive symptoms during IFN-alpha therapy in HIV-infected patients with CHC...
  58. ncbi A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study
    Agathe Leon
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    PLoS ONE 6:e14515. 2011
    ..This clinical scenario requires a new approach to simplify follow-up appointments and facilitate access to healthcare professionals...
  59. ncbi Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial
    Jose M Miro
    Institut d Investigacions Biomediques August Pi Sunyer Hospital Clinic, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 43:79-89. 2006
    ..To our knowledge, no randomized trials have evaluated whether prophylaxis against toxoplasmic encephalitis can be safely discontinued after the CD4+ T cell count increases in response to highly active antiretroviral therapy...
  60. ncbi Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy
    Jordi P Guallar
    Department of Biochemistry and Molecular Biology and Institut de Biomedicina IBUB, University of Barcelona, and CIBER Fisiopatología de Obesidad y Nutrición, Instituto de Salud Carlos III, Barcelona, Spain
    AIDS 22:575-84. 2008
    ..To elucidate the molecular basis of the progressive enlargement of dorso-cervical adipose tissue, the so-called 'buffalo hump', that appears in a sub-set of patients with HIV-1/HAART-associated lipodystrophy...
  61. ncbi A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk
    Mar Masia
    Department of Clinical Medicine, Infectious Diseases Unit, Hospital General Universitario de Elche, University Miguel Hernandez, Elche, Alicante, Spain
    J Antimicrob Chemother 64:589-98. 2009
    ..We evaluated the efficacy and safety of an intensive versus a standard intervention in HIV-infected patients with moderate-high cardiovascular risk...
  62. ncbi Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy
    Victor Asensi
    Infectious Diseases Unit, Hospital Central de Asturias, Oviedo University School of Medicine, Celestino Villamil s n, 33004 Oviedo, Spain
    Clin Infect Dis 39:240-7. 2004
    ..Echographically measured PRFD is associated with lipodystrophy and could be used as an early predictor of this syndrome in treatment-naive patients starting HAART...
  63. ncbi Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Belvitge, L Hospitalet de Llobregat, Barcelona, Spain
    Curr HIV Res 10:673-8. 2012
    ..To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice...
  64. ncbi Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients
    Alba Diaz
    Department of Pathology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 24:2029-39. 2010
    ..The factors associated with fibrosis in lymphoid tissue in long-term treated HIV-infected patients and their correlation with immune reconstitution were assessed...
  65. ncbi Short communication: reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy
    Oscar Miro
    Mitochondrial Research Laboratory, Department of Internal Medicine, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute IDIBAPS, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 19:1027-32. 2003
    ..Mitochondrial abnormalities had almost disappeared later when the patient became asymptomatic. Our findings support the hypothesis that MRC dysfunction stands at the basis of HAART-related hyperlactatemia...
  66. ncbi Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003)
    Omar Sued
    Servicios de Enfermedades Infecciosas, , , Universidad de Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Enferm Infecc Microbiol Clin 24:238-44. 2006
    ..HAART given during primary HIV infection was effective, but was associated with a high percentage of adverse effects...
  67. ncbi Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults
    Esteban Martinez
    Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, E 08036 Barcelona, Spain
    Clin Infect Dis 35:130-9. 2002
    ..For patients with concurrent meningitis, high doses of cefotaxime could be used if the MIC for cefotaxime was < or =1 microg/mL. Early recognition of heart failure and surgery may help to decrease mortality...
  68. ncbi Impact of lipodystrophy on the quality of life of HIV-1-infected patients
    Jordi Blanch
    Clinical Institute of Psychiatry and Psychology, Hospital Clinic Universitari de Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 31:404-7. 2002
    ..Lipodystrophy (LD) represents an important problem for HIV-1-infected patients receiving highly active antiretroviral therapy (HAART), although its impact on quality of life (QoL) has not been properly studied...
  69. ncbi Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving post-exposure prophylaxis
    Felipe Garcia
    Infectious Diseases Unit, University of Barcelona, Barcelona, Spain
    Antivir Ther 7:195-7. 2002
    ..This antiretroviral regimen seems to have no effect on lymphocyte T cell subsets, however, it could have an immune-modulator role, inducing an increase in the proliferative responses to mitogens...
  70. ncbi Polymorphic receptors of the innate immune system (MBL/MASP-2 and TLR2/4) and susceptibility to pneumococcal bacteremia in HIV-infected patients: a case-control study
    Juan P Horcajada
    Infectious Diseases Service, Hospital Clinic Universitari de Barcelona, Barcelona, Spain
    Curr HIV Res 7:218-23. 2009
    ..In HIV infected patients, no association between the presence of deficient polymorphisms of MBL2, MASP2, TLR2 and TLR4 and the incidence of pneumococcal bacteremia was found...
  71. ncbi Assessing the long-term viability of facial fat grafts: an objective measure using computed tomography
    Joan Fontdevila
    Department of Plastic Surgery, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Aesthet Surg J 28:380-6. 2008
    ..Autologous fat transplantation for soft tissue augmentation is a commonly used technique without a universally accepted approach. The literature includes a variety of reports describing varying degrees of success or failure...
  72. ncbi Current perspectives on HIV-associated lipodystrophy syndrome
    Ana Milinkovic
    Clinical Institute of Infections and Immunology, Institu d Investigacions Biomédiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
    J Antimicrob Chemother 56:6-9. 2005
    ..The issue of body composition has become extremely important for the adequate management of HIV-infected patients...
  73. ncbi Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy
    Pere Domingo
    Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    AIDS Rev 14:112-23. 2012
    ..In the context of HIV-1-infected patients under long-term antiretroviral therapy, fat toxicity is still the dark side of the rainbow...
  74. ncbi Decreased pregnancy rate after in-vitro fertilization in HIV-infected women receiving HAART
    Oriol Coll
    Clinica Eugin, IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 20:121-3. 2006
    ..Subclinical hypogonadism mediated by immunosuppression may explain these observations, suggesting the need to optimize the immunological status of the patient before considering assisted reproduction treatments...
  75. ncbi Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy
    Pilar Navarrete
    Infectious Diseases Unit, Clinic Institute of Infectious Diseases and Immunology, Faculty of Medicine, University of Barcelona, Barcelona, Spain
    Antivir Ther 8:635-7. 2003
    ..No correlation was observed after 1 year of antiretroviral therapy. A protease inhibitor-containing regimen was the best predictor of good tonsillar tissue virological response...
  76. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
    Montserrat Laguno
    Infectious Diseases Unit, the Pathology Service, , University of Barcelona, Spain
    AIDS 18:F27-36. 2004
    ..565). CONCLUSION: PEG-INF + RBV was significantly more effective than INF + RBV for the treatment of chronic hepatitis C in HIV co-infected patients, mainly of genotype 1 or 4...
  77. ncbi Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy
    Anna Suy
    Obstetric and Gynecological Service, Hospital Clinic of the Institute of Biomedical Investigations, August Pi i Sunyer Hospital, University of Barcelona, Barcelona, Spain
    AIDS 20:59-66. 2006
    ..183; 95% CI, 0.054-0.627; P = 0.007) were risk factors in HIV-infected women. CONCLUSIONS: HIV infection treated with HAART prior to pregnancy was associated with a significantly higher risk for pre-eclampsia and fetal death...
  78. ncbi Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study
    Alejandra Biglia
    Infectious Diseases Unit, Hospital Clinic-Institut d'Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 39:1514-9. 2004
    ..8-32.2; P=.003) were independent factors associated with gynecomastia. CONCLUSIONS: The data suggest that gynecomastia among HIV-infected patients is related to hypogonadism, rather than to an adverse effect of antiretroviral drugs...
  79. ncbi Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy
    Giovanni Guaraldi
    Universita di Modena e Reggio Emilia, Modena, Italy
    Antivir Ther 12:1059-65. 2007
    ..Both psychological and organic factors have been recognized to be associated with sexual dysfunction in HIV-infected individuals...
  80. ncbi Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir
    Anna Ochoa de Echaguen
    Hospital Mutua de Terrassa, Terrassa, Spain
    AIDS 19:1385-91. 2005
    ....
  81. ncbi Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy
    Timothy W Schacker
    Department of Medicine, University of Minnesota, MMC 250, 516 Delaware Street, Minneapolis MN 55455, USA
    J Infect Dis 186:1092-7. 2002
    ....
  82. ncbi The NEFA study: results at three years
    Esteban Martinez
    AIDS Rev 9:62. 2007
  83. ncbi Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study
    Cristina Mussini
    Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Azienda Policlinico, Modena, Italy
    Clin Infect Dis 38:565-71. 2004
    ..Recurrent cryptococcal infection should be suspected in patients whose serum cryptococcal antigen test results revert back to positive after discontinuation of maintenance therapy...
  84. ncbi The role of viruses in the aetiology of community-acquired pneumonia in adults
    Maria Angeles Marcos
    Department of Microbiology, Hospital Clinic i Provincial de Barcelona, Spain
    Antivir Ther 11:351-9. 2006
    ..We aimed to study the incidence and clinical characteristics of community-acquired pneumonia (CAP) due to respiratory viruses in adults adding PCR to routine conventional laboratory tests...
  85. ncbi Prevention strategies for cardiovascular disease in HIV-infected patients
    James H Stein
    Circulation 118:e54-60. 2008